Angelini Pharma, part of the privately held Angelini Industries, and Quiver Bioscience, a biotech innovator focused on CNS disorders, have announced a multi-year collaboration and licensing agreement aimed at developing novel therapies for genetic epilepsies.

 

The partnership combines Quiver’s cutting-edge drug discovery platform, AI models, and proprietary data assets with Angelini Pharma’s deep expertise in brain health and epilepsy drug development. 

 

Under the deal, Quiver will receive an undisclosed advance payment and research support, with potential milestone payments of up to $120 million and additional royalties tied to future drug targets. Angelini Pharma gains exclusive access to data generated through the collaboration during the research term.

 

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, Chief Scientific Officer at Angelini Pharma. 

 

“The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.”

 

The collaboration will focus on Developmental and Epileptic Encephalopathies (DEEs), a group of rare childhood disorders that cause severe, treatment-resistant seizures and a range of neurodevelopmental symptoms. 

 

Despite recent treatment approvals, effective therapies remain limited. Quiver’s platform leverages human neuronal models, single-cell transcriptomics, optical electrophysiology, and AI to accelerate the discovery of precision therapies for these complex conditions.

 

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” said Graham T. Dempsey, Co-founder and CEO of Quiver Bioscience. 

 

“Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers. We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”

 

“This new partnership is another step forward to advance our strategic priorities, strengthen our global presence and potentially expand our pipeline of innovative medicines and promising candidates,” said Sergio Marullo di Condojanni, CEO of Angelini Pharma.

 

“It follows a number of strategic acquisitions and collaboration agreements that we have entered over the course of the past two years and will further boost our leadership and portfolio in brain health.”